TrialAn Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease
Trial details
- Registry ID
- NCT04514367
- Phase
- Phase 2
ANNX
Annexon, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
7Trials in this database
10Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity sourceStudy of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)
Trial details
- Registry ID
- NCT04569435
- Phase
- Phase 2
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
Trial details
- Registry ID
- NCT04656561
- Phase
- Phase 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
Trial details
- Registry ID
- NCT04691570
- Phase
- Phase 2
Efficacy and Safety of ANX005 in Subjects With Guillain-Barré Syndrome
Trial details
- Registry ID
- NCT04701164
- Phase
- Phase 3
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
Trial details
- Registry ID
- NCT06510816
- Phase
- Phase 3
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Trial details
- Registry ID
- NCT07020819
- Phase
- Phase 3
Latest recorded trial changes
An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease
NCT04514367 · Annexon, Inc.
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Safety and tolerability of intravenous ANX005 administered for up to 22 weeks in subjects with, or at risk for, manifest Huntington's Disease; measure: Pharmacokinetics (PK) of ANX005; measure: Pharmacodynamics (PD) effects of ANX005
+ Updated value
measure: Number of Participants With Treatment-Emergent Adverse Events (TEAEs); measure: Actual Dose of ANX005 Administered on Day 1; measure: Actual Dose of ANX005 Administered on Week 22; measure: Area Under the Concentration Versus Time Curve From Time 0 to t (AUC0-t) of ANX005 at Day 1; measure: CSF Free Complement Component 1q (C1q) at Day 1; measure: Blood Free C1q at Day 1; measure: Change From Baseline in Complement C4a in CSF at Week 24; measure: Change From Baseline in Complement C4a in CSF at Week 36; measure: Change From Baseline in CSF NfL Level at Week 24; measure: Change From Baseline in CSF NfL Level at Week 36; measure: Change From Baseline in Blood NfL Level at Week 24; measure: Change From Baseline in Blood NfL Level at Week 36
The saved outcome text may be shortened. Check the source for full wording.
Primary completion date
Recorded edit− Previous value
2022-01-28
+ Updated value
2022-08-29
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
NCT04691570 · Annexon, Inc.
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Safety: Treatment-emergent adverse events (TEAEs); measure: Change in disease activity biomarkers
+ Updated value
measure: Number of Participants With Treatment-emergent Adverse Events (TEAEs); measure: Maximum Change From Baseline in Hemoglobin Levels; measure: Change From Baseline in Lactate Dehydrogenase Levels at Day 71; measure: Change From Baseline in Percentage of Reticulocytes/Total Cells Count at Day 71; measure: Change From Baseline in Haptoglobin Levels at Day 71; measure: Change From Baseline in Total Bilirubin Levels at Day 71; measure: Change From Baseline in Indirect Bilirubin Levels at Day 71
The saved outcome text may be shortened. Check the source for full wording.
Enrollment · participant count
Recorded edit− Previous value
count: 6; type: ACTUAL
+ Updated value
count: 7; type: ACTUAL
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816 · Annexon, Inc.
Primary outcomes · main study measures
Text edit · unverified significance− Previous value
measure: Proportion of patients experiencing a best corrected visual acuity (BCVA) ≥15-letter loss from baseline through the primary timepoint as assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) chart at any two consecutive visits.
+ Updated value
measure: Proportion of Participants Experiencing a Best Corrected Visual Acuity (BCVA) ≥15-letter Loss from Baseline Through Month 15 as Assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart at Any Two Consecutive Visits
The saved outcome text may be shortened. Check the source for full wording.
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
NCT07020819 · Annexon, Inc.
Primary completion date
Recorded edit− Previous value
2026-12
+ Updated value
2026-12-31
Recruitment status
Recorded edit− Previous value
Not yet recruiting
+ Updated value
Recruiting
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816 · Annexon, Inc.
Participant count type
Recorded edit− Previous value
Estimated
+ Updated value
Actual
Enrollment · participant count
Recorded edit− Previous value
count: 630; type: ESTIMATED
+ Updated value
count: 659; type: ACTUAL
Recruitment status
Recorded edit− Previous value
Recruiting
+ Updated value
Active not recruiting